Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.38 |
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.36 |
| ▸ | NPY4R | P50391 | 5/20 | 0.36 |
| ▸ | NPY1R | P25929 | 3/20 | 0.36 |
| ▸ | NPY2R | P49146 | 2/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322781 | 0.86 | DPP8 (0.44) | DPP7DPP4ARG1DPP8DPP9 | |
| SCHEMBL10730573 | 0.86 | DPP8 (0.44) | DPP7DPP4ARG1DPP8DPP9 | |
| SCHEMBL24322721 | 0.83 | GAA (0.47) | DPP7DPP4ARG1DPP8DPP9 | |
| SCHEMBL11534938 | 0.83 | GAA (0.47) | DPP7DPP4ARG1DPP8DPP9 | |
| SCHEMBL24322731 | 0.83 | DPP8 (0.38) | DPP7DPP4ARG1DPP8DPP9 | |
| SCHEMBL27296297 | 0.83 | ARG1 (0.35) | DPP7DPP4ARG1DPP8DPP9 | |
| SCHEMBL11551371 | 0.82 | DPP7 (0.41) | DPP7DPP4ARG1DPP8DPP9 | |
| SCHEMBL17313875 | 0.81 | USP2 (0.43) | DPP7 | |
| SCHEMBL17313876 | 0.81 | USP2 (0.43) | DPP7 | |
| SCHEMBL24322693 | 0.80 | ITGB3 (0.43) | DPP7DPP4DPP8DPP9ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | DPP7 367/4885DPP4 532/4885ARG1 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.